# Somatuline Predictive Factors in Acromegaly and NET

> **NCT01840449** · — · COMPLETED · sponsor: **Ipsen** · enrollment: 156 (actual)

## Conditions studied

- Acromegaly
- Neuroendocrine Tumours

## Interventions

- **DRUG:** Somatuline Autogel® 60, 90 or 120 mg

## Key facts

- **NCT ID:** NCT01840449
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2016-07
- **Final completion:** 2017-05
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01840449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01840449, "Somatuline Predictive Factors in Acromegaly and NET". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01840449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*